Control of Ticks Systemically with Merck MK-933, an Avermectin

The full text article is not available for purchase.

The publisher only permits individual articles to be downloaded by subscribers.


Merck MK -933 (7-[[2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-3-O-methyl-α-L-arabino-hexopyranosyl]oxy]-3',4',5'6,6',7,10,11,14,15,17a,20,20a,20b-tetradecahydro-20,20b-dihydroxy-5',6,8,19-tetramethyl-6'-(1-methylpropyl)spiro[11,15-methano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,2'-[2H]pyran]-17-one), an avermectin given orally to cattle daily by capsule, was highly effective in preventing engorgement and reproduction of adults of six species of three-host ticks—Amblyomma americanum (L.), A. cajennense (F.), A. maculatum Koch, Dermacentor andersoni Stiles, D. variabilis (Say), and Rhipicephalus sanguineus (Latreille)—and all parasitic stages of a one-host species—D. albipictus (Packard)—at dosages of >50 g/kg per day. A daily subcutaneous injection of 10 g/kg per day afforded complete control, but a similar injection of 5 g/kg per day was not completely effective. MK-933 formulated as sustained-release tablets or boluses designed to release ca. 50 g/kg per day was also effective, but the sustained-release devices eroded at rates higher or lower than those anticipated. The activity of this chemical at such low dosage levels makes it an excellent candidate as an acaricide for the control of ticks systemically.

Document Type: Research Article

Publication date: August 1, 1981

More about this publication?
Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more